trastuzumab deruxtecan
daiichi sankyo,astrazeneca
[' gem ', 'tdxd', 'rux,(-crux),(-trux)']
tdxd deruxtecan in biliary tract cancer. #asco2023,
in gem refractory or intolerant: the dcr, median pfs, mos were 81.8%, 4.4 months (mo) (95% ci, 2.8 8.3), 7.1 mo (95% ci, 4.7 14.6),
we need individualized therapy in gbc, utterly genomic chaos! 
MD, DM Medical Oncologist. One Earth, One Family, One Future. Gallbladder Cancer is passion. Pharmacoeconomics. Views are personal.